BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.
BioCryst Pharmaceuticals, Inc.(納斯達克:BCRX)今天宣佈展示了六張海報,包括APeX-N試驗的首箇中期真實世界證據,以及突出展示醫療保健提供者(HCP)與遺傳性血管性水腫(HAE)患者之間共享決策(SDM)的價值,以實現最佳患者結局。
The company is presenting the posters at the 7th Bradykinin Symposium in Berlin from September 5-6, 2024.
該公司將在2024年9月5日至6日於柏林舉行的第7屆激肽酶抑制劑研討會上展示這些海報。
- APeX-N interim results: Oral berotralstat for HAE prophylaxis in Europe
- HCP and patient perspectives: HAE long-term prophylaxis and shared decision-making
- Adverse health outcomes and perspectives of androgen use in HAE
- Evaluation of adherence to berotralstat in patients with hereditary angioedema
- Tolerability and effectiveness of berotralstat for long-term prophylaxis in HAE
- Effectiveness and safety of berotralstat in HAE with normal C1-inhibitor
- APeX-N中期結果:歐洲遺傳性血管性水腫(HAE)口服berotralstat預防
- HCP和患者的觀點:HAE長期預防和共同決策
- HAE雄激素使用的不良健康結果和觀點
- 評估遺傳性血管性水腫患者對berotralstat的依從性
- HAE的長期預防中berotralstat的耐受性和有效性
- HAE合併正常C1抑制蛋白時berotralstat的有效性和安全性
APeX-N interim results
APeX-N中期結果
APeX-N is a European multi-center observational study assessing the safety (primary objective), effectiveness and quality of life (secondary objectives) of berotralstat 150 mg in routine clinical use. This interim analysis included 56 patients from the United Kingdom, France, Germany and Sweden.
APeX-N是一項歐洲多中心觀察研究,評估berotralstat在常規臨床使用中的安全性(主要目標)、有效性和生活質量(次要目標)。這次中期分析包括來自英國、法國、德國和瑞典的56名患者。
Non-serious gastrointestinal adverse events were reported in 12.5 percent of patients. Seven percent (n=4) of patients discontinued treatment (three due to unsatisfactory response, one to participate in a clinical trial). One patient had a severe HAE attack but continued treatment.
12.5%的患者報告非嚴重胃腸道不良事件。7%的患者(n=4)中止治療(其中三人由於治療效果不佳,一人蔘與臨床試驗)。一名患者發生了嚴重HAE發作,但繼續治療。
"These initial data from APeX-N in Europe reinforce and closely replicate the clinical trial and real-world evidence of berotralstat as the first oral prophylaxis for HAE," said Dr. Sorena Kiani, consultant immunologist at Royal Free London NHS Foundation.
這些來自歐洲APeX-N的初步數據證實並緊密複製了berotralstat作爲HAE的首個口服預防措施的臨床試驗和真實世界證據,皇家自由倫敦NHS基金會的免疫學顧問Sorena Kiani博士說。
HCP and patient perspectives: HAE long-term prophylaxis and shared decision-making
HCP和患者的觀點:HAE長期預防和共同決策
This study, conducted in Germany, explored the dynamics between HCPs and patients in HAE management, identifying barriers to SDM and strategies to improve it. Ten HCPs participated in 60 minute interviews and simulated patient consultations. Eight HAE patients participated in 30 minute interviews. Participants then convened in structured focus groups to discuss their findings.
這項在德國進行的研究探討了HCP和患者在HAE管理中的動態,並確定了SDm的障礙和改進策略。十名HCP參加了60分鐘的面試和模擬患者諮詢。八名HAE患者參加了30分鐘的面試。參與者隨後召開結構化的焦點小組討論他們的發現。
The participants identified a need for enhanced HCP awareness of patient perspectives, more comprehensive HCP-patient conversations and improved education about HAE treatment management.
參與者發現HCP需要增加對患者觀點的認識,進行更全面的HCP-患者交流,並改善有關HAE治療管理的教育。
"The findings from this study support the need for further insights to develop future guidance and HAE management strategies to facilitate successful shared decision making and improved patient quality of life," said Dr. Emel Aygören-Pürsün, department for children and adolescents, University Hospital Frankfurt, Germany.
這項研究的發現支持了進一步洞察以制定未來的指導和HAE管理策略,以促進成功的共享決策和改善患者的生活質量,德國法蘭克福大學醫院兒童和青少年部門的Emel Aygören-Pürsün博士表示。